Physician profile
Anna Price
NPI 1902553613
$2,002.28
in general payments reported to CMS, 2019-2025
20 companies · $526 in 2025
The $526 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $419 · 2023: $668 · 2024: $390 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $315.29 | 2022-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $304.66 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $202.38 | 2022-2025 | Rexulti, Jynarque |
| Novo Nordisk INC | $179.68 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $175.37 | 2024 | Farxiga, Lokelma |
| Teva Pharmaceuticals USA, INC. | $146.13 | 2025 | Austedo Xr |
| Calliditas Therapeutics US INC. | $127.89 | 2022-2023 | Tarpeyo |
| Abbott Laboratories | $125.00 | 2022 | |
| Amgen INC. | $110.45 | 2023-2024 | Parsabiv, Tavneos, Otezla |
| Dexcom, INC. | $71.81 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $42.32 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $33.80 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $33.31 | 2023 | Krystexxa |
| Travere Therapeutics, INC. | $32.32 | 2023 | |
| Globus Medical, INC. | $18.24 | 2025 | Senza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.08 | 2025 | |
| Aurinia Pharma U.S., INC. | $17.80 | 2022 | |
| Pfizer INC. | $17.38 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.91 | 2025 | Xifaxan |
| Eisai INC. | $13.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.